Summary

Eligibility
for people ages 22 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around

Description

Summary

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

Keywords

Bowel; Stricture, dcb, bowel stricture, drug coated balloon, paclitaxel coated balloon, Pathologic Constriction, GIE Medical ProTractX3 TTS DCB

Eligibility

You can join if…

Open to people ages 22 years and up

  1. Age ≥ 22
  2. Diagnosis of symptomatic benign bowel stricture with at least 2 previous dilations.
  3. Willing and able to complete protocol required follow up
  4. Willing and able to provide written informed consent
  5. Stricture length ≤ 5 cm

You CAN'T join if...

  1. Female subjects who are pregnant or breastfeeding or plan to get pregnant in next 12 months
  2. Contraindication to endoscopy, anesthesia, or deep sedation.
  3. Suspicion of malignant bowel stricture NOTE: Biopsy should be taken for every stricture during the initial endoscopy, however endoscopic balloon dilation may proceed without awaiting results if suspicion for malignancy is low in the opinion of the investigator.
  4. Benign stricture due to extrinsic compression
  5. Stricture is not amenable to standard balloon dilation (e.g. severe angulation, unable to pass guidewire, etc.)
  6. Stricture complicated with abscess, fistula, perforation, leakage or varices
  7. Stricture segment has moderate to severe active inflammation at the time of treatment. Moderate to severe inflammation is defined as any one of; ulcers >0.5cm in diameter, ulcerated surface >10%, affected (inflamed) surface >50%, marked erythema, absent vascular pattern, significant friability, or erosions
  8. Multiple clinically significant strictures unable to be treated with a single balloon (i.e. total segment length must be ≤5cm) NOTE: Clinically significant strictures include those that are unable to be passed by the endoscope.
  9. Received steroid injections into target stricture in the last 8 weeks
  10. Stricture is not able to be dilated to ≥15mm in small bowel or ≥18mm in large bowel
  11. Diagnosis of metastatic cancer of any type that is not considered in remission or non-metastatic cancer that may require radiation treatment in the pelvic region (e.g. prostate cancer)
  12. Suspected perforation of gastrointestinal tract
  13. Active systemic infection
  14. Allergy to paclitaxel
  15. Severe coagulation disorders or current use of anticoagulant or antiplatelet medication that cannot be safely managed per relevant societal guidelines
  16. Chronic systemic steroid use (defined as greater than 10 mg/day) for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use
  17. Condition requiring treatment in urgent setting
  18. Life expectancy of less than 24 months
  19. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety, such as recent myocardial infarction, severe pulmonary disease, bleeding diathesis, large thoracic aneurysm, pharyngeal or cervical deformity, etc.
  20. Current participation in another pre-market drug or medical device clinical study unless in long term follow-up

Locations

  • University of California, Irvine accepting new patients
    Irvine California 92697-7600 United States
  • Cedars Sinai accepting new patients
    Los Angeles California 90048 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
GIE Medical
ID
NCT05561127
Phase
Phase 3
Study Type
Interventional
Participants
Expecting 171 study participants
Last Updated